Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

BACKGROUND: Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Bellmunt, Joaquim, Lalani, Aly-Khan A., Jacobus, Sussana, Wankowicz, Stephanie A., Polacek, Laura, Takeda, David Y., Harshman, Lauren C., Wagle, Nikhil, Moreno, Irene, Lundgren, Kevin, Bossé, Dominick, Van Allen, Eliezer M., Choueiri, Toni K., Rosenberg, Jonathan E.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173710/
https://ncbi.nlm.nih.gov/pubmed/30220708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0261-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados